+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Antibody Drug"

From
Serum-free Media Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

Serum-free Media Market Analysis & Forecast to 2024-2034

  • Report
  • May 2024
  • 200 Pages
  • Global
From
AI Impact on Bispecific Antibodies Market - Pulse Report - Product Thumbnail Image

AI Impact on Bispecific Antibodies Market - Pulse Report

  • Report
  • May 2026
  • 26 Pages
  • Global
From
Gastric Cancer Pipeline Analysis Report - Product Thumbnail Image

Gastric Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
T-Cell Malignancies - Pipeline Insight, 2025 - Product Thumbnail Image

T-Cell Malignancies - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 280 Pages
  • Global
From
Esophageal Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Esophageal Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 280 Pages
  • Global
From
Cancer Cachexia - Pipeline Insight, 2025 - Product Thumbnail Image

Cancer Cachexia - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 80 Pages
  • Global
From
From
Anti-CD20 Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD20 Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Anti-CD40 Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD40 Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Nasopharyngeal Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Nasopharyngeal Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Biliary Tumor - Pipeline Insight, 2025 - Product Thumbnail Image

Biliary Tumor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Anti-CD19 Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD19 Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Anti-CD38 antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD38 antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
CD137 Agonist Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

CD137 Agonist Antibody - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Influenza - Pipeline Insight, 2025 - Product Thumbnail Image

Influenza - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
AXL Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

AXL Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Biliary Tract Cancer (BTC)- Pipeline Insight, 2025 - Product Thumbnail Image

Biliary Tract Cancer (BTC)- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Loading Indicator

The Antibody Drug market is a subset of the biotechnology industry that focuses on the development and commercialization of therapeutic antibodies. Antibody drugs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. These drugs are designed to target specific molecules in the body, such as proteins, hormones, and enzymes, and can be used to block or activate certain pathways. Antibody drugs are typically administered intravenously or subcutaneously, and can be used in combination with other drugs or therapies. The Antibody Drug market is highly competitive, with many companies investing in research and development to create new and improved treatments. Companies in the market are focused on developing novel antibodies, as well as improving existing treatments. Additionally, companies are investing in the development of biosimilars, which are generic versions of existing antibody drugs. Some companies in the Antibody Drug market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, Regeneron, Roche, and Sanofi. Show Less Read more